Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma

Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.

[1]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[2]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[3]  R. Motzer,et al.  Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). , 2015 .

[4]  Z. Dezső,et al.  Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage , 2014, Vascular cell.

[5]  M. Schmidinger.  Third-line dovitinib in metastatic renal cell carcinoma. , 2014, The Lancet. Oncology.

[6]  C. Porta,et al.  Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[7]  R. Motzer,et al.  A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) , 2013, Cancer Chemotherapy and Pharmacology.

[8]  J. Soria,et al.  Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma , 2013, Clinical Cancer Research.

[9]  C. Porta,et al.  Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients , 2012, Oncology.

[10]  Michael Jeffers,et al.  Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. , 2012, The Lancet. Oncology.

[11]  J. Wanders,et al.  A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours , 2012, British Journal of Cancer.

[12]  C. Porta,et al.  Treatment selection in metastatic renal cell carcinoma: expert consensus , 2012, Nature Reviews Clinical Oncology.

[13]  G. Jayson,et al.  A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Demidov,et al.  Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma , 2011, Scandinavian journal of urology and nephrology.

[15]  D. Berney,et al.  Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib , 2011, Oncogene.

[16]  K. Nishio,et al.  Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[17]  Karl J. Dykema,et al.  Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study , 2010, Molecular Cancer Therapeutics.

[18]  R. Kahnoski,et al.  Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. , 2010, Cancer research.

[19]  Michael B Atkins,et al.  Resistance to targeted therapy in renal-cell carcinoma. , 2009, The Lancet. Oncology.

[20]  M. Korc,et al.  The role of fibroblast growth factors in tumor growth. , 2009, Current cancer drug targets.

[21]  D. Hanahan,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[22]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[23]  M. Atkins,et al.  Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer , 2007, Clinical Cancer Research.

[24]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[25]  J. Serth,et al.  Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels , 2005, Journal of Cancer Research and Clinical Oncology.

[26]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[27]  T. Shuin,et al.  Levels of angiogenesis and expression of angiogenesis‐related genes are prognostic for organ‐specific metastasis of renal cell carcinoma , 2005, Cancer.

[28]  A. Bikfalvi,et al.  Regulation of vascular development by fibroblast growth factors , 2003, Cell and Tissue Research.

[29]  F. Marshall.  Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. , 2002, The Journal of urology.

[30]  S. Hubbard,et al.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.

[31]  A. Czarnecka,et al.  Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. , 2014, Biochimica et biophysica acta.